Veru Inc. is an oncology biopharmaceutical company developing novel medicines for prostate and breast cancer. Veru's prostate cancer pipeline includes zuclomiphene citrate (VERU-944, cis-clomiphene) ,VERU-111 (bisindole), and Veru 100. Zuclomiphene citrate is an estrogen receptor agonist being evaluated in a Ph2 trial to treat hot flashes caused by hormone treatment for men with advanced prostate cancer. VERU-111 is an oral, next-generation, first-in-class selective small molecule that targets and disrupts alpha and beta subunits of microtubules in cells to treat metastatic prostate cancer patients whose disease are resistant to one androgen receptor targeting agent. Veru 100 is a 3 month GnRH antagonist administered via small volume subcutaneous injection. The company is also advancing a 505 (b)(2) product, a combination tablet of Tadalafil and Finasteride, NDA submitted February 2021.The company's new breast cancer pipeline includes Enobosarm (AR agonist for AR+/ER+/HER2- metastic breast cancer) and VERU 111(taxane resistant triple neg breast). VERU has also completed a Ph2 for SARS-COV2 in high risk ARDS using VERU 111, a Ph3 is planned Q2 21 .